387 related articles for article (PubMed ID: 32572726)
1. Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome.
Kong XF; Worley L; Rinchai D; Bondet V; Jithesh PV; Goulet M; Nonnotte E; Rebillat AS; Conte M; Mircher C; Gürtler N; Liu L; Migaud M; Elanbari M; Habib T; Ma CS; Bustamante J; Abel L; Ravel A; Lyonnet S; Munnich A; Duffy D; Chaussabel D; Casanova JL; Tangye SG; Boisson-Dupuis S; Puel A
J Clin Immunol; 2020 Aug; 40(6):807-819. PubMed ID: 32572726
[TBL] [Abstract][Full Text] [Related]
2. Expression of interferon-γ, interferon-α and related genes in individuals with Down syndrome and periodontitis.
Tanaka MH; Giro EM; Cavalcante LB; Pires JR; Apponi LH; Valentini SR; Spolidório DM; Capela MV; Rossa C; Scarel-Caminaga RM
Cytokine; 2012 Dec; 60(3):875-81. PubMed ID: 22995210
[TBL] [Abstract][Full Text] [Related]
3. Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S; Asano T; Moriya K; Boisson-Dupuis S; Kobayashi M; Casanova JL; Puel A
J Clin Immunol; 2020 Nov; 40(8):1065-1081. PubMed ID: 32852681
[TBL] [Abstract][Full Text] [Related]
4. Down syndrome and type I interferon: not so simple.
Malle L; Bogunovic D
Curr Opin Immunol; 2021 Oct; 72():196-205. PubMed ID: 34174697
[TBL] [Abstract][Full Text] [Related]
5. Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1.
Baris S; Alroqi F; Kiykim A; Karakoc-Aydiner E; Ogulur I; Ozen A; Charbonnier LM; Bakır M; Boztug K; Chatila TA; Barlan IB
J Clin Immunol; 2016 Oct; 36(7):641-8. PubMed ID: 27379765
[TBL] [Abstract][Full Text] [Related]
6. Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility.
Aue A; Szelinski F; Weißenberg SY; Wiedemann A; Rose T; Lino AC; Dörner T
Rheumatology (Oxford); 2020 Nov; 59(11):3435-3442. PubMed ID: 32357246
[TBL] [Abstract][Full Text] [Related]
7. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease.
Kong XF; Vogt G; Itan Y; Macura-Biegun A; Szaflarska A; Kowalczyk D; Chapgier A; Abhyankar A; Furthner D; Djambas Khayat C; Okada S; Bryant VL; Bogunovic D; Kreins A; Moncada-Vélez M; Migaud M; Al-Ajaji S; Al-Muhsen S; Holland SM; Abel L; Picard C; Chaussabel D; Bustamante J; Casanova JL; Boisson-Dupuis S
Hum Mol Genet; 2013 Feb; 22(4):769-81. PubMed ID: 23161749
[TBL] [Abstract][Full Text] [Related]
8. Major differences in the responses of primary human leukocyte subsets to IFN-beta.
van Boxel-Dezaire AH; Zula JA; Xu Y; Ransohoff RM; Jacobberger JW; Stark GR
J Immunol; 2010 Nov; 185(10):5888-99. PubMed ID: 20956346
[TBL] [Abstract][Full Text] [Related]
9. Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome.
Malle L; Martin-Fernandez M; Buta S; Richardson A; Bush D; Bogunovic D
Immunity; 2022 Nov; 55(11):2074-2084.e5. PubMed ID: 36243008
[TBL] [Abstract][Full Text] [Related]
10. Dysregulated IFN-γ signals promote autoimmunity in STAT1 gain-of-function syndrome.
Largent AD; Lambert K; Chiang K; Shumlak N; Liggitt D; Oukka M; Torgerson TR; Buckner JH; Allenspach EJ; Rawlings DJ; Jackson SW
Sci Transl Med; 2023 Jul; 15(703):eade7028. PubMed ID: 37406138
[TBL] [Abstract][Full Text] [Related]
11. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity.
Araya P; Waugh KA; Sullivan KD; Núñez NG; Roselli E; Smith KP; Granrath RE; Rachubinski AL; Enriquez Estrada B; Butcher ET; Minter R; Tuttle KD; Bruno TC; Maccioni M; Espinosa JM
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24231-24241. PubMed ID: 31699819
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes.
Balistreri CR; Ammoscato CL; Scola L; Fragapane T; Giarratana RM; Lio D; Piccione M
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260695
[TBL] [Abstract][Full Text] [Related]
13.
Zimmerman O; Olbrich P; Freeman AF; Rosen LB; Uzel G; Zerbe CS; Rosenzweig SD; Kuehn HS; Holmes KL; Stephany D; Ding L; Sampaio EP; Hsu AP; Holland SM
Front Immunol; 2019; 10():1433. PubMed ID: 31354696
[TBL] [Abstract][Full Text] [Related]
14. Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks.
Ling KH; Hewitt CA; Tan KL; Cheah PS; Vidyadaran S; Lai MI; Lee HC; Simpson K; Hyde L; Pritchard MA; Smyth GK; Thomas T; Scott HS
BMC Genomics; 2014 Jul; 15(1):624. PubMed ID: 25052193
[TBL] [Abstract][Full Text] [Related]
15. Enhanced osteoclastogenesis in patients with MSMD due to impaired response to IFN-γ.
Tsumura M; Miki M; Mizoguchi Y; Hirata O; Nishimura S; Tamaura M; Kagawa R; Hayakawa S; Kobayashi M; Okada S
J Allergy Clin Immunol; 2022 Jan; 149(1):252-261.e6. PubMed ID: 34176646
[TBL] [Abstract][Full Text] [Related]
16. Signal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NFκB to Enhance Pro-inflammatory Transcription.
Piaszyk-Borychowska A; Széles L; Csermely A; Chiang HC; Wesoły J; Lee CK; Nagy L; Bluyssen HAR
Front Immunol; 2019; 10():1253. PubMed ID: 31231385
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune Regulator Deficiency Results in a Decrease in STAT1 Levels in Human Monocytes.
Zimmerman O; Rosen LB; Swamydas M; Ferre EMN; Natarajan M; van de Veerdonk F; Holland SM; Lionakis MS
Front Immunol; 2017; 8():820. PubMed ID: 28769929
[TBL] [Abstract][Full Text] [Related]
18. The multifaceted balance of TNF-α and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines.
Smiljanovic B; Grün JR; Biesen R; Schulte-Wrede U; Baumgrass R; Stuhlmüller B; Maslinski W; Hiepe F; Burmester GR; Radbruch A; Häupl T; Grützkau A
J Mol Med (Berl); 2012 Nov; 90(11):1295-309. PubMed ID: 22610275
[TBL] [Abstract][Full Text] [Related]
19. Altered immune parameters correlate with infection-related hospitalizations in children with Down syndrome.
Martínez E; Castañeda D; Jaramillo S; Iregui A; Quiñonez T; Rodríguez JA; Herrera E; Gómez AM; Rondón MA; Prieto JC; Angel J; Franco MA; Mesa MC
Hum Immunol; 2016 Jul; 77(7):594-9. PubMed ID: 27166175
[TBL] [Abstract][Full Text] [Related]
20. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
